rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Envista Holdings Corporation

NVST · NYSE

Health CareMedical DevicesNot moving yet

NVST stood above a rising 150-day average in 41 of the last 52 weekly readings, and has been out of that trend for the last 6 weeks. It is 10.6% below that average now. Medical Devices: 27% of its 181 stocks in an uptrend (−9 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 6
Industry in uptrend
27% -9 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$1.0M
Officials’ trades on record
1
Institutions holding
353 (-8)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 41 of 52 weeks.

17 Apr – 16 Oct
19%29%40%Apr 26Jun 26Jul 26Sep 26Oct 26

Medical Devices: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$560K$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

1 disclosed lines: House 1, Senate 0, executive 0; 1 people.

WhoDidAmountTraded
Pete Sessions House: U.S. House ClerkTX17soldspouse$1k–$15k6 Jun 2024filed 6 Jun 2024

Insiders

Buy orders, 12 months0
Sale orders, 12 months2
Buyers · sellers0 · 1
WhoDidSharesTraded
Mischa ReisSVP, Strategy & Bus. Dev.sold8,000at $27.5020 Aug 2026filed 24 Aug 2026
Mischa ReisSVP, Strategy & Bus. Dev.sold4,041at $30.0010 Feb 2026filed 11 Feb 2026
Mischa ReisSVP, Strategy & Bus. Dev.sold5,634at $30.0010 Feb 2026filed 11 Feb 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders353-8 on the quarter
New · exited50 · 59
Reported value$5.0B

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
BlackRock, Inc.added · filed 7 Aug 202618,437,542$485.8M+584,715+3.3%
ARIEL INVESTMENTS, LLCreduced · filed 14 Aug 20269,818,177$258.7M-1,045,415−9.6%
DIMENSIONAL FUND ADVISORS LPreduced · filed 11 Aug 20269,566,949$252.1M-213,999−2.2%
VANGUARD PORTFOLIO MANAGEMENT LLCreduced · filed 13 Aug 20267,487,670$197.3M-79,051−1.0%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 20267,337,916$193.4M+19,335+0.3%
MORGAN STANLEYreduced · filed 13 Aug 20266,436,043$169.6M-2,357,094−26.8%
Gates Capital Management, Inc.added · filed 14 Aug 20265,552,383$146.3M+189,672+3.5%
STATE STREET CORPadded · filed 7 Aug 20265,329,275$140.5M+100,517+1.9%
ALLIANCEBERNSTEIN L.P.added · filed 14 Aug 20265,213,644$132.3M+185,033+3.7%
ARROWSTREET CAPITAL, LIMITED PARTNERSHIPadded · filed 13 Aug 20264,847,940$127.7M+1,989,647+69.6%
31 Mar 2023 – 30 Jun 2026
256307357Mar 23Dec 23Dec 24Sep 25Jun 26

Everyone who traded it

Eric D. Hammes Company insiderChief Financial Officer · last 25 Aug 20261 · 0
Robert Befidi Company insiderPresident, Diagnostics · last 25 Aug 20260 · 0
Stefan Nilsson Company insiderPresident, Nobel Biocare · last 25 Aug 20260 · 0
Veronica Acurio Company insiderPresident, Orthodontics · last 25 Aug 20260 · 0
Mischa Reis Company insiderSVP, Strategy & Bus. Dev. · last 20 Aug 20261 · 12
Paul A. Keel Company insiderChief Executive Officer · last 18 Aug 20261 · 0
Christine A. Tsingos Company insiderDirector · last 19 May 20260 · 0
Daniel Raskas Company insiderDirector · last 19 May 20260 · 0
James Andrew Pierce Company insiderDirector · last 19 May 20260 · 0
Kieran Gallahue Company insiderDirector · last 19 May 20260 · 0
R. Scott Huennekens Company insiderDirector · last 19 May 20260 · 0
Vivek Jain Company insiderDirector · last 19 May 20260 · 0

Same industry

RCEL Avita MedicalLeading+100%
ATRC AtriCureLeading+49%
HAE HaemoneticsLeading+48%
HTFL HeartflowLeading+40%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202554.7%
Operating profit marginFY 2025 · to 31 Dec 20257.9%
Free cash flow marginFY 2025 · to 31 Dec 20258.5%
Return on capital employedFY 2025 · to 31 Dec 20254.5%
Cash conversionFY 2025 · to 31 Dec 2025587%
Debt to equityFY 2025 · to 31 Dec 20250.47×
Research spendFY 2025 · to 31 Dec 20254.2%
Share count trendFY 2025 · to 6 Feb 20260.0%
Cash and equivalentsFY 2025 · to 31 Dec 2025$1.2B
Free cash flowFY 2025 · to 31 Dec 2025$230.4M

Analyst forecasts

No analyst forecasts yet.